Journal Mobile Options
Table of Contents
Vol. 149, No. 4, 2009
Issue release date: July 2009
Section title: Original Paper
Int Arch Allergy Immunol 2009;149:359–368
(DOI:10.1159/000205582)

Effect of Enzymatically Modified Isoquercitrin, a Flavonoid, on Symptoms of Japanese Cedar Pollinosis: A Randomized Double-Blind Placebo-Controlled Trial

Kawai M.a · Hirano T.a · Arimitsu J.a · Higa S.c · Kuwahara Y.a · Hagihara K.a · Shima Y.a · Narazaki M.a · Ogata A.a · Koyanagi M.d · Kai T.d · Shimizu R.d · Moriwaki M.d · Suzuki Y.d · Ogino S.b · Kawase I.a · Tanaka T.a
aDepartment of Respiratory Medicine, Allergy and Rheumatic Diseases and bSchool of Allied Health Sciences, Osaka University Graduate School of Medicine, cTondabayashi Hospital and dSan-Ei-Gen F.F.I., Suita, Japan

Do you have an account?

Register and profit from personalized services (MyKarger) Login Information

Please create your User ID & Password





Contact Information









I have read the Karger Terms and Conditions and agree.

Register and profit from personalized services (MyKarger) Login Information

Please create your User ID & Password





Contact Information









I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger (new!)
  • Unrestricted printing, no saving restrictions for personal use
  • Reduced rates with a PPV account
read more

Direct: USD 38.00
Account: USD 26.50

Select

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply

Rental: USD 8.50
Cloud: USD 20.00

Select

Subscribe

  • Access to all articles of the subscribed year(s) guaranteed for 5 years
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates


Select


Article / Publication Details

First-Page Preview
Abstract of Original Paper

Received: 4/24/2008
Accepted: 11/20/2008
Published online: 3/17/2009
Issue release date: July 2009

Number of Print Pages: 10
Number of Figures: 6
Number of Tables: 1

ISSN: 1018-2438 (Print)
eISSN: 1423-0097 (Online)

For additional information: http://www.karger.com/IAA

Abstract

Background: Flavonoids exert antiallergic and antioxidant effects. We investigated the efficacy of enzymatically modified isoquercitrin (EMIQ), a flavonoid, to relieve symptoms of pollinosis. Methods: In a parallel-group, double-blind placebo-controlled study design, 20 subjects with Japanese cedar pollinosis took two capsules daily of 100 mg EMIQ or a placebo for 8 weeks during the pollen season. Subjective symptoms and activities of daily living (ADL) scores were recorded every day, and the quality of life (QOL) score was obtained every 4 weeks. Blood sampling was performed before and after the study to measure serum cytokines, chemokines, IgE, quercetin and oxidized biomarkers. Results: During the entire study period, total ocular score and ocular itching score for the EMIQ group were significantly lower (p < 0.05) than for the placebo group. When limited to the individual periods, total symptom score for the EMIQ group was significantly lower (p < 0.05, week 4–5) than that for the placebo group while other scores for the EMIQ group, such as total nasal score (p = 0.06, week 4–5), nasal obstruction score (p = 0.08, week 4–5), lacrimation score (p = 0.06, week 5–6), ocular congestion score (p = 0.08, week 4–7) and ADL score (p = 0.08, week 4–7), all tended to be lower. The levels of serum cytokines such as interleukin (IL)-4, IL-5, IL-12, IL-13, interferon-γ, and eotaxin and IgE were not significantly downregulated by the intake of EMIQ but the serum concentrations of oxidized low-density lipoprotein and thymus and activation-regulated chemokine were reduced. Conclusion: Intake of the quercetin glycoside EMIQ was safe and influenced ocular symptoms caused by pollinosis.

© 2009 S. Karger AG, Basel


  

Author Contacts

Correspondence to: Dr. Toshio Tanaka
Department of Respiratory Medicine, Allergy and Rheumatic Diseases
Osaka University Graduate School of Medicine
2-2 Yamada-oka, Suita City, Osaka 565-0871 (Japan)
Tel. +81 6 6879 3838, Fax +81 6 6879 3839, E-Mail ttanak@imed3.med.osaka-u.ac.jp

  

Article Information

Received: April 24, 2008
Accepted after revision: November 20, 2008
Published online: March 17, 2009
Number of Print Pages : 10
Number of Figures : 6, Number of Tables : 1, Number of References : 44

  

Publication Details

International Archives of Allergy and Immunology

Vol. 149, No. 4, Year 2009 (Cover Date: July 2009)

Journal Editor: Valenta R. (Vienna)
ISSN: 1018-2438 (Print), eISSN: 1423-0097 (Online)

For additional information: http://www.karger.com/IAA


Article / Publication Details

First-Page Preview
Abstract of Original Paper

Received: 4/24/2008
Accepted: 11/20/2008
Published online: 3/17/2009
Issue release date: July 2009

Number of Print Pages: 10
Number of Figures: 6
Number of Tables: 1

ISSN: 1018-2438 (Print)
eISSN: 1423-0097 (Online)

For additional information: http://www.karger.com/IAA


Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.